Boston Scientific Invests $1.5B for 34% MiRus Stake with $3B TAVR Option
Boston Scientific invested $1.5 billion to acquire a 34% stake in MiRus, plus an exclusive option to buy the SIEGEL TAVR business for up to $3 billion if clinical and regulatory goals are met. The nickel-free rhenium-frame valve uses an 8 French sheath in a 1,025-patient STAR trial.
1. Investment and Strategic Option
Boston Scientific has committed $1.5 billion to purchase a 34% stake in MiRus and secured an exclusive option to acquire the SIEGEL balloon-expandable TAVR business for up to $3 billion if clinical and regulatory conditions are met. The agreement also grants rights to MiRus’ mitral and tricuspid valve products under separate terms, with the company’s adjusted 2026 EPS forecast unchanged by the deal.
2. Innovative SIEGEL Valve Design
The SIEGEL transcatheter aortic valve features a nickel-free rhenium alloy frame coated with nitric oxide and an open-cell architecture for precise placement. All valve sizes—23 mm, 26 mm, and 29 mm—can be delivered through an 8 French sheath, about half the diameter of current balloon-expandable systems.
3. STAR Pivotal Trial and Market Return
MiRus has launched the STAR pivotal trial to evaluate safety and effectiveness in 1,025 patients across low, intermediate, and high surgical risk categories. Boston Scientific’s investment marks its reentry into the balloon-expandable TAVR space as aortic stenosis diagnosis rates rise globally.